A randomized, double-blind, placebo-controlled study showed subjects taking the key ResiFlex-CFM ingredient reported significantly improved scores for Western Ontario and McMaster Universities Osteo-Arthritis Index (WOMAC) measurements of joint function, stiffness and comfort.
A clinical trial was carried out on the functional ResiFlex-CFM ingredient. This randomized, double-blind, placebo-controlled study included a study group given the functional ResiFlex-CFM ingredient, and a group given a placebo. The groups were sex-matched and recruited from the ages of 40 to 75 years, and neither the subjects nor the investigators knew which treatments were given to which subjects.
At baseline, 30, 60, and 90 days of taking the supplements, the study subjects completed the Western Ontario and McMaster Universities Osteo-Arthritis Index (WOMAC) for scoring joint function, stiffness, and comfort. This scale was used because it is a validated, high performance instrument for evaluative research in joint health with multiple validations of its construct validity, reliability, responsiveness, and relative efficiency. Results showed that the ResiFlex-CFM functional compound improved WOMAC scores of joint function, stiffness, and comfort across the board, significantly outperforming the placebo after only 30 days in all of these measures.